Abstract Number: 798 • 2013 ACR/ARHP Annual Meeting
Targeting Ultrasound Remission In Early Rheumatoid Arthritis – Results Of The Taser Study
Background/Purpose: The TaSER study (NCT00920478) is an open label randomized clinical trial with blinded assessments of outcome. It was designed to test whether the efficacy…Abstract Number: 799 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiological Outcomes Of Two Years Remission Steered Treatment In Early Arthritis Patients
Background/Purpose: To evaluate outcomes after 2 years of remission steered therapy in early arthritis patients. Methods: 610 patients with early rheumatoid or undifferentiated arthritis (UA)…Abstract Number: 800 • 2013 ACR/ARHP Annual Meeting
A Strategy For Selecting Individuals With RA For Reduction Of Anti-TNF Therapy Using Combined Clinical and Ultrasound Assessment
Background/Purpose: Reducing the dose of biological therapy may be possible for patients with rheumatoid arthritis (RA) who have achieved remission or low disease activity (LDA). …Abstract Number: 801 • 2013 ACR/ARHP Annual Meeting
Remaining Pain Is Common In Early RA Patients Treated With Methotrexate – Results From The EIRA Cohort and The Swedish Rheumatology Quality Register
Background/Purpose: Although treatment with methotrexate is often efficient in decreasing inflammation and joint destruction in RA, several patients report remaining pain at follow-up (Taylor P…Abstract Number: 802 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across The Rheumatoid Arthritis Clinical Program
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis extended the evaluation of malignancies that occurred…Abstract Number: 803 • 2013 ACR/ARHP Annual Meeting
The Risk Of Serious Infections In Patients Receiving Rituximab For Rheumatoid Arthritis: Results From The British Society For Rheumatology Biologics Register-Rheumatoid Arthritis
Background/Purpose: In the United Kingdom (UK), rituximab (RTX), an anti-CD20 monoclonal antibody, is currently used to treat patients with rheumatoid arthritis (RA) who have failed…Abstract Number: 804 • 2013 ACR/ARHP Annual Meeting
Tumour Necrosis Factor Inhibitors and The Risk Of Acute Coronary Syndrome In Rheumatoid Arthritis – a National Cohort Study
Background/Purpose: The high risk of ischemic heart disease (IHD) in patients with rheumatoid arthritis (RA) has been linked to inflammation and disease severity. Treatment with…Abstract Number: 805 • 2013 ACR/ARHP Annual Meeting
Good Response On Tumour Necrosis Factor Inhibitors Are Associated With a Decreased Risk Of Acute Coronary Syndromes In Patients With Rheumatoid Arthritis
Background/Purpose: Inflammatory activity, as well as traditional cardiovascular risk factors, have been suggested to underlie the increased risk of coronary disease in patients with rheumatoid…Abstract Number: 806 • 2013 ACR/ARHP Annual Meeting
Risk Of Cancer Recurrence Or New Tumors In RA Patients With Prior Malignancies Treated With Various Biologic Agents
Background/Purpose: If patients with rheumatoid arthritis (RA) have a history of malignancy, the choice of treatment is an important clinical question. The aim is to…Abstract Number: 807 • 2013 ACR/ARHP Annual Meeting
Perioperative Use Of Anti-Rheumatic Agents Does Not Increase Early Postoperative Infection Risks: A Veteran Affairs’ Administrative Database Study
Background/Purpose: Evidences for perioperative management of disease modifying anti-rheumatic drugs (DMARDs) and biologic agents (BA) are sparse, and limited mainly to methotrexate & specific surgeries…Abstract Number: 768 • 2013 ACR/ARHP Annual Meeting
Inhibition Of X-Box Binding Protein 1 (XBP1) Is Chondroprotective By Promoting Autophagy and Inhibiting Catabolic Responses
Background/Purpose: Chondrocyte stress responses to biomechanical injury and joint inflammation, and associated changes in differentiation and function, provide a foundation upon which cartilage injury and…Abstract Number: 769 • 2013 ACR/ARHP Annual Meeting
Synovial Wnt and WISP1 Expression Induces Expression Of Cartilage-Degrading Metalloproteinases In The Synovium
Background/Purpose: Although many osteoarthritis (OA) patients show significant synovial involvement, consequences are largely unknown. Previously, we found strong upregulation of Wnts 2b and 16 and…Abstract Number: 770 • 2013 ACR/ARHP Annual Meeting
Suppressor Of Cytokine Signaling-3 Is a Critical Regulator Of gp130 Cytokine Signaling In Articular Chondrocytes
Background/Purpose: Cartilage damage is a key feature of inflammatory and degenerative arthritis and an important determinant of patient outcomes. Chondrocytes are the only cells in…Abstract Number: 771 • 2013 ACR/ARHP Annual Meeting
The S100A9 Inhibitor Paquinimod (ABR-215757) Reduces Synovial Activation, Osteophyte Formation and Cartilage Damage In Experimental Osteoarthritis
Background/Purpose: Synovial activation is present in a large subset of osteoarthritis (OA) patients and it is thought to play an important role in the development…Abstract Number: 772 • 2013 ACR/ARHP Annual Meeting
Neovascularization and CD15s Influence Long Distance Migration Of Synovial Fibroblasts From Patients With Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) synovial fibroblasts (SF) are central cells of cartilage destruction and neoangiogenesis. RASF show an increased migratory potential in the synovium towards…
ACR Meeting Abstracts